AstraZeneca Moves Toward the Oral GLP-1 Market with Elecoglipron Jennifer Hardy Jun 9 4 min read The race to develop effective oral GLP-1 medications for obesity is heating up, and AstraZeneca is officially making its move
Eli Lilly) a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist has emerged as the latest option for weight loss and glycaemic control
Established in 2010 with corporate headquarters in Chandigarh, the company operates state-of-the-art, ISO-certified, and WHO-GMP compliant manufacturing facilities in Baddi, Himachal Pradesh Business Type Distributor, Supplier Payment Mode Cash Advance (CA), Cash in Advance (CID), Cheque, Telegraphic Transfer (T/T), Others Related Products Explore Related Categories More Products From This Seller Compare With Similar Products Price Or Price Range 4500 INR (Approx.) 450 INR (Approx.) Minimum Order Quantity 3 Bottle/Bottles 100000 Piece/Pieces Pacakaging (Quantity Per Box) SEALED NEW IN BOX Typically 10 vials per box but varies based on manufacturer specifications
The plant's small, reddish fruits, also called Wu-Wei-Zi berries, have a tradition of over 2000 years in East Asia